• Oncoinvent granted new Chief Medical Officer Zuzana Jiráková Trnková 20,000 share options on October 28, 2026, under its long-term incentive program.
• Each option carries a NOK 67.35 strike price, entitling the holder to one share upon exercise; the grant requires no payment.
• No options vest during the first 12 months; 13/48 vest in month 13.
• Remaining options vest in monthly installments of 1/48, subject to continued employment.
• Unexercised options expire seven years from the grant date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202610280202BITN____UKPR__EN_20261027-BIT-0872-0) on October 28, 2026, and is solely responsible for the information contained therein.